methyl salicylate has been researched along with Migraine Disorders in 1 studies
methyl salicylate: used in over-the-counter liniments, ointments, lotions for relief of musculoskeletal aches and pains; has hemolytic effect on human & sheep erythrocytes; RN given refers to parent cpd; structure in Merck Index, 9th ed, #5990
methyl salicylate : A benzoate ester that is the methyl ester of salicylic acid.
Migraine Disorders: A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The mean migraine duration was 18." | 3.11 | A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study. ( Arkuszewski, M; Ecochard, L; Kim, BK; Li, Z; Lian, Y; Su, W; Wan, Q; Wang, H; Wang, SJ; Wen, S; Yin, F; Yu, S; Yu, T; Zhou, J, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, S | 3 |
| Kim, BK | 3 |
| Wang, H | 3 |
| Zhou, J | 3 |
| Wan, Q | 3 |
| Yu, T | 3 |
| Lian, Y | 3 |
| Arkuszewski, M | 3 |
| Ecochard, L | 3 |
| Wen, S | 3 |
| Yin, F | 3 |
| Li, Z | 3 |
| Su, W | 3 |
| Wang, SJ | 3 |
1 trial available for methyl salicylate and Migraine Disorders
| Article | Year |
|---|---|
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Topics: Acute Pain; Antibodies, Monoclonal, Humanized; Asia; Camphor; Female; Headache; Humans; Male; Mentho | 2022 |